Proteomics success story. Novel biomarkers for DNA damage response pathways: insights and applications for cancer therapy.
O'Connor
Mark
M
KuDOS Pharmaceuticals Limited, 327 Cambridge Science Park, Milton Road, Cambridge CB4 0WG, UK. mjoconnor@kudospharma.co.uk
D064007:Ataxia Telangiectasia Mutated Proteins; D015415:Biomarkers / Q000032:analysis*; D001943:Breast Neoplasms / Q000188:drug therapy; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors; D004249:DNA Damage; D004260:DNA Repair / Q000187:drug effects*; D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors; D015180:Electrophoresis, Gel, Two-Dimensional; D005260:Female; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D040901:Proteomics; D025521:Tumor Suppressor Proteins / Q000037:antagonists & inhibitors
D015415:Biomarkers; D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D025521:Tumor Suppressor Proteins; C576324:ATM protein, human; D064007:Ataxia Telangiectasia Mutated Proteins; D017346:Protein Serine-Threonine Kinases